Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire

Abstract

Psoriatic arthritis (PsA) is an inflammatory arthritis associated with irreversible joint damage in a subset of individuals. There is a need to screen early for this condition to prevent damage. To meet this need, we have developed the psoriatic arthritis screening and evaluation (PASE) questionnaire. The 15-item PASE questionnaire was administered to 190 individuals with either psoriasis or PsA. The PASE questionnaire was readministered to a subset of individuals with PsA in order to assess test–retest reliability and sensitivity-to-change. Receiver operator curves were constructed to optimize sensitivity and specificity for the diagnosis of PsA. Of the 190 participating in the study, 19.5% (37/191) participants were diagnosed with PsA. PASE total scores ranged from 15 to 74 (possible range, 15–75). The PsA group had a median Total score of 51 (25th and 75th percentile 44 and 57), and non-PsA group had a median total score of 34 (25th and 75th percentile 21 and 49) (p < 0.001). A PASE total score of 44 was able to distinguish PsA from non-PsA participants with 76% sensitivity and 76% specificity. Furthermore, 13 of the 15 items demonstrated significant test–retest reliability as assessed by Pearson correlation coefficient (r ≥ 0.5). PASE was sensitive-to-change with therapy; PASE scores were significantly lower for PsA individuals after systemic therapy (p < 0.034). The PASE questionnaire is a valid and reliable tool to screen for active PsA among individuals with psoriasis. PASE scores may be used as a marker of therapeutic response.

Obesity and risk of incident psoriatic arthritis in US women

“…A total score of 47 or greater has been shown to identify PsA with high accuracy 13 14. We observed a positive association between PASE score and the 28-joint disease activity score (E. Soriano, personal communication, 2012).…”

“…We confirmed the diagnosis of PsA by using the psoriatic arthritis screening and evaluation (PASE) questionnaire, which includes both symptom and function scales 13 14. A total score of 47 or greater has been shown to identify PsA with high accuracy 13 14.…”

“…We observed a positive association between PASE score and the 28-joint disease activity score (E. Soriano, personal communication, 2012). PASE also has good test–retest precision and is sensitive to change to therapy 13. Furthermore, PASE can distinguish between the symptoms of PsA and osteoarthritis 14…”

Quantifying harmful effects of psoriatic diseases on quality of life: Cardio-metabolic outcomes in psoriatic arthritis study (COMPASS)

“…Screening tools like the Toronto psoriatic arthritis screen (ToPAS), Psoriatic arthritis screening and evaluation (PASE), and Psoriasis epidemiology screening project (PEST) questionnaires have been developed for screening for psoriatic arthritis in patients with psoriasis [43][44][45]. Our data also suggests that patients with psoriasis may benefit from more formal screening so that early interventions exist for patients suffering from mood or psychiatric disorders such as depression and anxiety.…”

Screening Instruments for Psoriatic Arthritis

“…In a recent study, Walsh, et al 1 sought to compare 3 published, validated screening tools for psoriatic arthritis (PsA): the Psoriasis Epidemiology Screening project (PEST), the Toronto Psoriatic Arthritis Screen (ToPAS), and the Psoriatic Arthritis Screening and Evaluation (PASE) 2,3,4,5 . We would like to address how PASE may not have been appropriately compared in this setting.…”